Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, day 3, 10 and 14
Awards & highlights
Study Summary
This trial aims to determine if PF-07817883 treatment can safely reduce the virus that causes COVID 19 in adults with symptoms.
Eligible Conditions
- COVID-19
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, day 3, 10 and 14
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, day 3, 10 and 14
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Secondary outcome measures
Change from baseline in SARS-CoV-2 RNA level
Incidence of AEs leading to discontinuations.
Incidence of Serious Adverse Events (SAE)
+4 moreTrial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: Arm 3: high doseExperimental Treatment1 Intervention
Group II: Arm 2: medium doseExperimental Treatment1 Intervention
Group III: Arm 1: low doseExperimental Treatment1 Intervention
Group IV: Arm 4: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PF-07817883
2022
Completed Phase 2
~350
Find a Location
Who is running the clinical trial?
PfizerLead Sponsor
4,581 Previous Clinical Trials
14,633,989 Total Patients Enrolled
67 Trials studying COVID-19
1,437,656 Patients Enrolled for COVID-19
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,486 Previous Clinical Trials
11,810,864 Total Patients Enrolled
50 Trials studying COVID-19
1,426,477 Patients Enrolled for COVID-19
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have another infection in your body that could affect how well the study treatment works.You have a type of cancer in your blood or immune system, or you are taking medication that weakens your immune system for another type of cancer.
Research Study Groups:
This trial has the following groups:- Group 1: Arm 3: high dose
- Group 2: Arm 1: low dose
- Group 3: Arm 2: medium dose
- Group 4: Arm 4: Placebo
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger